clinical trials for glp 1 GLP1 agonists: current and future landscape of patients with metabolic dysfunction GLP-1 Drugs: The Science and

No medication exists to lower B12 levels specifically, and there is no clinical need for one because the B12 itself isnt causing harm

It was originally developed by Novo Nordisk and has been the subject of multiple Phase I and Phase II clinical trials, making it one of the better-characterised GHS peptides in terms of safety and pharmacokinetic data

Its safety profile is well-established over decades of clinical use

The active ingredients in each form share similar molecular structures but differ in stability and formulation

Gregg EW, Hora I, Benoit SR

While generally used in weight management, research is continually evolving, opening the door for new therapeutic indications